Alector, Inc.

ALEC

Alector, Inc.

ALEC

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-03Shares Purchased (TTM):0Shares Sold (TTM):546,957

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:84,228,314Shares Outstanding:110,590,014Institutional Ownership Pct.:76.16%

Earnings Market Reaction:

Filing Date:2026-05-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	77	66	77	45	38	33	37	48	73	75	102	132
Marketable Securities Current	130	190	215	263	317	380	420	456	490	474	487	499
Prepaid Expense And Other Assets Current	9	10	9	12	12	11	12	16	19	17	14	10
Assets Current	215	266	300	319	367	425	469	520	581	566	613	648
Property Plant And Equipment Net	10	11	13	14	16	17	18	20	21	22	23	24
Operating Lease Right Of Use Asset	13	14	16	17	19	20	21	23	24	25	26	26
Restricted Cash Noncurrent	2	2	2	2	2	2	2	2	2	2	2	2
Other Assets Noncurrent	0	0	4	4	5	5	6	6	7	7	9	9
Assets	240	293	335	356	408	468	516	571	635	622	672	709
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	2	5	2	2	2	5	4	5	4	5	5
Accrued Liabilities Current	11	19	18	14	17	29	26	23	19	30	30	23
Contract With Customer Liability Current	7	7	12	13	22	24	55	64	73	83	81	69
Contract With Customer Refund Liability Current	0	11	22	34	45	49	38	39	38	39	24	21
Operating Lease Liability Current	9	9	9	9	9	9	9	9	9	8	8	8
Short Term Borrowings	1	0	-	-	-	0	-	-	-	-	-	-
Liabilities Current	41	70	80	84	110	125	143	148	165	178	155	132
Contract With Customer Liability Noncurrent	163	165	167	169	170	172	193	200	205	211	230	245
Long Term Debt Noncurrent	8	9	10	10	9	9	-	-	-	0	-	-
Contract With Customer Refund Liability Noncurrent	-	0	0	0	0	9	35	44	57	67	92	101
Operating Lease Liability Noncurrent	16	17	19	21	23	24	26	28	29	30	32	33
Other Liabilities Noncurrent	2	2	1	1	1	1	1	1	1	1	1	1
Liabilities	230	263	278	285	314	342	397	420	457	488	510	512
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,005	1,003	992	971	964	956	945	936	925	844	832	822
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	0	1	-1	-0	0	-1	-1
Retained Earnings Accumulated Deficit	-995	-972	-935	-900	-870	-829	-827	-785	-746	-710	-669	-624
Stockholders Equity	10	31	58	71	95	127	119	151	179	134	163	196
Liabilities And Stockholders Equity	240	293	335	356	408	468	516	571	635	622	672	709
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	111	110	107	101	100	99	98	97	96	85	84	84
Shares Outstanding	111	110	107	101	100	99	98	97	96	85	84	84

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-11.48%	-23.77%	-38.93%	-	-	-	-	-	-	-	-	-
2025	27.88%	42.31%	69.23%	60.96%	112.33%	2.74%	2.31%	11.54%	49.23%	-14.23%	7.53%	-9.62%
2024	-5.20%	-12.52%	25.05%	7.54%	0.20%	-3.05%	-50.57%	-66.03%	-65.84%	-21.51%	-46.51%	-29.07%
2023	-	-	-	-10.94%	3.85%	-20.15%	-3.30%	38.78%	5.04%	-14.69%	-27.39%	-22.40%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	5.25	3.83	3.76	3.78	3.34	3.40	3.29	3.52	3.53	3.18	3.95	4.90
Quick Ratio	5.04	3.68	3.64	3.64	3.23	3.31	3.21	3.41	3.41	3.08	3.86	4.82
Working Capital	174.12M	196.95M	220.42M	234.82M	256.88M	299.76M	326.84M	372.02M	416.47M	387.86M	457.75M	515.72M
Leverage & Debt
Debt to Equity	22.11	8.57	4.81	4.01	3.32	2.69	3.34	2.79	2.55	3.64	3.14	2.61
Debt Ratio	0.96	0.90	0.83	0.80	0.77	0.73	0.77	0.74	0.72	0.78	0.76	0.72
Efficiency & Turnover
Asset Turnover TTM	0.06	0.06	0.16	0.18	0.17	0.18	0.10	0.09	0.14	0.14	0.13	0.13
Per Share Metrics
Diluted EPS TTM	-1.13	-1.39	-1.05	-1.15	-1.24	-1.23	-1.62	-1.66	-1.29	-1.56	-1.68	-1.71
Free Cash Flow Per Share TTM	-1.57	-1.79	-1.93	-2.15	-2.31	-2.39	-2.28	-2.25	-2.12	-2.23	-2.27	-2.33
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-739.70%	-741.30%	-179.14%	-165.80%	-165.25%	-144.19%	-301.10%	-338.94%	-150.75%	-156.33%	-165.84%	-153.73%
Net Profit Margin TTM	-680.83%	-679.16%	-156.03%	-142.10%	-139.74%	-118.39%	-257.54%	-290.66%	-125.11%	-134.34%	-146.80%	-140.18%
Growth Metrics
Net Revenue Growth (1Y)	-79.15%	-79.07%	12.26%	46.78%	-8.37%	3.60%	-36.14%	-45.84%	-23.30%	-27.36%	-27.68%	-66.06%
Net Income Growth (1Y)	1.58%	20.06%	-31.99%	-28.24%	2.34%	-8.70%	12.04%	12.31%	-10.36%	-2.19%	3.59%	-494.59%
EPS Growth (1Y)	-8.70%	12.59%	-35.35%	-30.89%	-3.41%	-20.85%	-3.57%	-3.00%	-20.59%	-3.67%	1.95%	-489.38%
Valuation Metrics
P/E TTM	-1.90	-1.12	-2.82	-1.22	-0.99	-1.53	-2.87	-2.73	-4.68	-5.12	-3.85	-3.51
P/B TTM	22.90	5.24	5.26	1.97	1.29	1.44	3.82	2.92	3.16	4.98	3.35	2.56
P/S TTM	12.91	7.63	4.40	1.73	1.38	1.82	7.39	7.94	5.86	6.88	5.65	4.92
Market Cap	237.77M	160.68M	303.69M	140.52M	122.26M	182.55M	454.44M	438.90M	564.74M	668.20M	543.85M	501.82M
Enterprise Value	168.73M	102.72M	234.95M	103.44M	91.90M	157.07M	415.74M	389.81M	490.64M	592.09M	440.34M	368.73M
Calculated Values
Free Cash Flow TTM	-173.20M	-184.07M	-197.58M	-216.01M	-230.08M	-231.16M	-222.26M	-217.95M	-199.04M	-186.73M	-190.12M	-194.45M
Net Debt	-69.04M	-57.96M	-68.74M	-37.08M	-30.36M	-25.48M	-38.71M	-49.09M	-74.10M	-76.10M	-103.51M	-133.09M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-03Sale

Owner: Wong-Sarad, Grace

Title: Principal Accounting Officer

Shares: 3,475

Price/Share: $1.88

Value: $6,533.00

Shares Owned: 95,461

Relationship: Officer

Ownership: Direct

2026-06-02Sale

Owner: Berkley, Neil Lindsay

Title: CFO & Chief Business Officer

Shares: 19,360

Price/Share: $1.97

Value: $38,139.20

Shares Owned: 379,900

Relationship: Officer

Ownership: Direct

2026-06-02Sale

Owner: Rosenthal, Arnon

Title: Chief Executive Officer

Shares: 87,216

Price/Share: $1.97

Value: $171,815.52

Shares Owned: 2,367,206

Relationship: Director,Officer

Ownership: Direct

2026-04-16Sale

Owner: Wong-Sarad, Grace

Title: Principal Accounting Officer

Shares: 1,820

Price/Share: $2.65

Value: $4,823.00

Shares Owned: 104,645

Relationship: Officer

Ownership: Direct

2026-03-10Sale

Owner: Wong-Sarad, Grace

Title: Principal Accounting Officer

Shares: 1,000

Price/Share: $2.65

Value: $2,650.00

Shares Owned: 106,465

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-03	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	3,475	1.88	$6,533.00	95,461	4
2026-06-02	Berkley, Neil Lindsay	Officer	CFO & Chief Business Officer	Direct	Sale	19,360	1.97	$38,139.20	379,900	4
2026-06-02	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	87,216	1.97	$171,815.52	2,367,206	4
2026-04-16	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	1,820	2.65	$4,823.00	104,645	4
2026-03-10	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	1,000	2.65	$2,650.00	106,465	4
2026-03-03	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	3,367	2.08	$7,003.36	107,465	4
2026-03-02	Berkley, Neil Lindsay	Officer	CFO & Chief Business Officer	Direct	Sale	29,649	2.12	$62,855.88	344,660	4
2026-03-02	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	8,071	2.12	$17,110.52	110,832	4
2026-03-02	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	81,864	2.12	$173,551.68	2,338,176	4
2026-02-26	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	4,079	2.50	$10,197.50	118,903	4
2025-12-05	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	4,753	1.21	$5,751.13	122,982	4
2025-12-03	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	8,056	1.12	$9,022.72	127,735	4
2025-12-03	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	41,687	1.12	$46,689.44	501,652	4
2025-12-03	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	104,347	1.12	$116,868.64	2,420,040	4
2025-12-03	Berkley, Neil Lindsay	Officer	Chief Bus Ofcr & Interim CFO	Direct	Sale	37,261	1.12	$41,732.32	374,309	4
2025-09-02	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	23,638	2.50	$59,095.00	543,339	4
2025-09-02	Berkley, Neil Lindsay	Officer	Principal Financial Officer	Direct	Sale	15,842	2.50	$39,605.00	346,570	4
2025-09-02	Wong-Sarad, Grace	Officer	Principal Accounting Officer	Direct	Sale	5,910	2.50	$14,775.00	103,448	4
2025-09-02	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	51,562	2.50	$128,905.00	2,350,220	4
2025-08-26	Hammond, Paula	Director	-	Direct	Sale	14,000	2.36	$33,040.00	74,909	4
2025-06-20	Yaffe, Kristine	Director	-	Direct	Sale	1,000	1.44	$1,440.00	95,409	4
2025-06-02	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	23,890	1.34	$32,012.60	512,252	4
2025-06-02	Grasso, Marc	Officer	Chief Financial Officer	Direct	Sale	16,488	1.34	$22,093.92	296,072	4
2025-06-02	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	52,087	1.34	$69,796.58	2,414,657	4
2025-03-03	Grasso, Marc	Officer	Chief Financial Officer	Direct	Sale	18,091	1.47	$26,593.77	312,560	4
2025-03-03	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	40,330	1.47	$59,285.10	2,466,744	4
2025-03-03	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	29,073	1.47	$42,737.31	536,142	4
2025-03-03	Romano, Gary	Officer	Chief Medical Officer	Direct	Sale	16,306	1.47	$23,969.82	332,977	4
2024-12-02	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	52,172	2.52	$131,473.44	2,507,074	4
2024-12-02	Grasso, Marc	Officer	Chief Financial Officer	Direct	Sale	16,489	2.52	$41,552.28	330,651	4
2024-12-02	Romano, Gary	Officer	Chief Medical Officer	Direct	Sale	14,892	2.52	$37,527.84	349,283	4
2024-12-02	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	26,500	2.52	$66,780.00	565,215	4
2024-09-03	Romano, Gary	Officer	Chief Medical Officer	Direct	Sale	8,478	4.88	$41,372.64	179,795	4
2024-09-03	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	13,926	4.88	$67,958.88	291,715	4
2024-09-03	Grasso, Marc	Officer	Chief Financial Officer	Direct	Sale	7,297	4.88	$35,609.36	130,740	4
2024-09-03	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	26,499	4.88	$129,315.12	1,948,746	4
2024-08-22	Scheller, Richard H	Director	-	Direct	Sale	44,250	5.16	$228,330.00	35,000	4
2024-08-12	Hammond, Paula	Director	-	Direct	Sale	10,500	5.06	$53,130.00	60,209	4
2024-08-12	Yaffe, Kristine	Director	-	Direct	Sale	5,000	5.06	$25,300.00	67,709	4
2024-06-03	Grasso, Marc	Officer	Chief Financial Officer	Direct	Sale	6,920	4.80	$33,216.00	138,037	4
2024-06-03	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	25,135	4.80	$120,648.00	1,975,245	4
2024-06-03	Romano, Gary	Officer	Chief Medical Officer	Direct	Sale	8,040	4.80	$38,592.00	188,273	4
2024-06-03	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	13,206	4.80	$63,388.80	305,641	4
2024-03-04	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	18,837	6.92	$130,352.04	2,000,380	4
2024-03-04	Grasso, Marc	Officer	Chief Financial Officer	Direct	Sale	5,716	6.92	$39,554.72	144,957	4
2024-03-04	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	10,169	6.92	$70,369.48	318,847	4
2024-03-04	Romano, Gary	Officer	Chief Medical Officer	Direct	Sale	6,001	6.92	$41,526.92	196,313	4
2023-12-04	Romano, Gary	Officer	Chief Medical Officer	Direct	Sale	5,035	5.56	$27,994.60	202,314	4
2023-12-04	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	12,519	5.56	$69,605.64	329,016	4
2023-12-04	Grasso, Marc	Officer	Chief Financial Officer	Direct	Sale	4,574	5.56	$25,431.44	150,673	4
2023-12-04	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	23,831	5.56	$132,500.36	2,019,217	4
2023-09-11	Polaris, Venture Manageme…	TenPercentOwner	-	Indirect	Sale	500,000	6.00	$3,000,000.00	10,853,817	4
2023-09-11	Mcguire, Terrance	Director,TenPercentOwner	-	Indirect	Sale	500,000	6.00	$3,000,000.00	10,853,817	4
2023-09-05	Romano, Gary	Officer	Chief Medical Officer	Direct	Sale	2,771	5.19	$14,381.49	99,349	4
2023-09-05	Kenkare-Mitra, Sara	Officer	President and Head of R&D	Direct	Sale	6,214	5.19	$32,250.66	177,935	4
2023-09-05	Grasso, Marc	Officer	Chief Financial Officer	Direct	Sale	1,114	5.19	$5,781.66	32,247	4
2023-09-05	Rosenthal, Arnon	Director,Officer	Chief Executive Officer	Direct	Sale	5,647	5.19	$29,307.93	1,645,448	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

76.16%

Inst. Shares: 84,228,314

Shares Outstanding: 110,590,014

2025-12-31

78.07%

Inst. Shares: 80,415,215

Shares Outstanding: 102,998,978

2025-09-30

67.77%

Inst. Shares: 69,526,848

Shares Outstanding: 102,597,601

2025-06-30

62.65%

Inst. Shares: 62,886,773

Shares Outstanding: 100,371,632

2025-03-31

70.35%

Inst. Shares: 69,924,116

Shares Outstanding: 99,398,200

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	84,228,314	110,590,014	76.16%
2025-12-31	80,415,215	102,998,978	78.07%
2025-09-30	69,526,848	102,597,601	67.77%
2025-06-30	62,886,773	100,371,632	62.65%
2025-03-31	69,924,116	99,398,200	70.35%
2024-12-31	71,071,888	96,588,177	73.58%
2024-09-30	70,459,405	97,519,595	72.25%
2024-06-30	70,651,619	96,674,921	73.08%
2024-03-31	71,533,224	93,810,177	76.25%
2023-12-31	61,235,197	83,733,730	73.13%
2023-09-30	59,620,401	83,927,961	71.04%
2023-06-30	56,570,424	83,497,125	67.75%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Alector, Inc. (ALEC) — SEC Financial Statements & Analysis

Alector, Inc. (ALEC) is a biological products, (no diagnostic substances) company. Alector, Inc. trades on Nasdaq as: ALEC. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Alector, Inc. reported a -79.15% year-over-year revenue growth, a Debt-to-Equity ratio of 22.11x, a Price-to-Sales (P/S) ratio of 12.91x (TTM), a Price-to-Book (P/B) ratio of 22.9 (TTM), at a market cap of $237.77M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -79.15%
Debt To Equity: 22.11x
P/S TTM: 12.91x
P/B TTM: 22.9
Market Cap: $237.77M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Alector, Inc. in?

Alector, Inc. (ALEC) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ALEC's market cap?

Alector, Inc. (ALEC) has a market capitalization of $237.77M as of 2026-03-31.

What exchange does ALEC trade on?

Alector, Inc. (ALEC) trades on the Nasdaq.

Alector, Inc. (ALEC) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.